Clarithromycin reduces Isus and Ito currents in human atrial myocytes with minor repercussions on action potential duration

Fundamental and Clinical Pharmacology

Volumn 17, Issue 6, 2003, Pages 691-701

  Gluais, Pascale ^a   Bastide, Michèle ^a,b   Grandmougin, Daniel ^c   Fayad, Georges ^c   Adamantidis, Monique ^a  

^a UNIV LILLE   (France)

^b IUT A de Lille   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Action potential; Clarithromycin; Human heart; Outward potassium currents

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; BUFLOMEDIL; CALCIUM CHANNEL L TYPE; CERIVASTATIN; CLARITHROMYCIN; DIGOXIN; FLUTICASONE; FORMOTEROL; FUROSEMIDE; GLYCERYL TRINITRATE; HEPARIN; ISOSORBIDE DINITRATE; LITHIUM; MOLSIDOMINE; OMEPRAZOLE; PRAVASTATIN; PROPRANOLOL; RAMIPRIL; SIMVASTATIN; AMINOPYRIDINE DERIVATIVE; POTASSIUM CHANNEL;

ADULT; AGED; ARTICLE; CALCIUM CURRENT; CARDIOTOXICITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM MUSCLE; HEART ELECTROPHYSIOLOGY; HEART MUSCLE CELL; HEART MUSCLE FIBER MEMBRANE; HEART MUSCLE FIBER MEMBRANE POTENTIAL; HEART VENTRICLE WALL; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MEMBRANE CURRENT; MICROELECTRODE; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; ACTION POTENTIAL; ANIMAL; CELL CULTURE; CYTOLOGY; DOSE RESPONSE; ELECTROPHYSIOLOGY; HEART ATRIUM APPENDAGE; HEART VENTRICLE; MIDDLE AGED; PHYSIOLOGY; RABBIT; TIME;

ACTION POTENTIALS; AGED; AMINOPYRIDINES; ANIMALS; ATRIAL APPENDAGE; CALCIUM CHANNELS, L-TYPE; CELLS, CULTURED; CLARITHROMYCIN; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; FEMALE; HEART VENTRICLES; HUMANS; MALE; MICROELECTRODES; MIDDLE AGED; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS; RABBITS; TIME FACTORS;

EID: 0344513990     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1472-8206.2003.00186.x     Document Type: Article

References (40)

1. Kamochi H., Nii T., Eguchi K. et al. Clarithromycin associated with torsades de pointes. Jpn. Circ. J. (1999) 63 421-422.
2. Lai D., Brown G., MacDonald I. Clarithromycin-induced prolonged QT syndrome. Can. J. Hosp. (1998) 49 33-35.
3. Lee K.L., Jim M.H., Tang S.C., Tai Y.T. QT prolongation and Torsades de Pointes associated with clarithromycin. Am. J. Med. (1998) 104 395-396.
4. Gray V.S. Syncopal episodes associated with cisapride and concurrent drugs. Ann. Pharmacother. (1998) 32 648-651.
5. Van Haarst A.D., Van 't Klooster G.A., Van Gerven J.M. et al. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clin. Pharmacol. Ther. (1998) 64 542-546.
6. Hayashi Y., Ikeda U., Hashimoto T., Watanabe T., Mitsuhashi T., Shimada K. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. Pacing Clin. Electrophysiol. (1999) 22 672-674.
7. Haverkamp W., Breithardt G., Camm A.J. et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc. Res. (2000) 47 219-233.
8. Gluais P., Bastide M., Caron J., Adamatidis M. Comparative effects of clarithromycin on action potential and ionic currents from rabbit isolated atrial and ventricular myocytes. J. Cardiovasc. Pharmacol. (2003) 41 506-517.
9. Abbott G.W., Sesti F., Splawski I. et al. MiRP1 forms LKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 16 175-187.
10. Sanguinetti M.C., Jiang C., Curran M.E., Keating M.T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 81 299-307.
11. Volberg W.A., Koci B.J., Su W., Lin J., Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. (2002) 302 320-327.
12. Wang Z., Fermini B., Nattel S. Rapid and slow components of delayed rectifier current in human atrial myocytes. Cardiovasc. Res. (1994) 28 1540-1546.
13. Wang Z., Fermini B., Nattel S. Effects of flecainide, quinidine, and 4-aminopyridine on transient outward and ultrarapid delayed rectifier currents in human atrial myocytes. J. Pharmacol. Exp. Ther. (1995) 272 184-196.
14. Hatem S.N., Benardeau A., Rucker-Martin C., Samuel J.L., Coraboeuf E., Mercadier J.J. Differential regulation of voltage-activated potassium currents in cultured human atrial myocytes. Am. J. Physiol. (1996) 271 1609-1619.
15. + current in human atrial myocytes. Br. J. Pharmacol. (1997) 122 291-301.
16. + current through a nifedipine inhibited inward channel. J. Pharmacol. Exp. Ther. (1998) 286 9-22.
17. Crumb W.J. Jr. Pigott J.D., Clarkson C.W. Description of a nonselective cation current in human atrium. Circ. Res. (1995) 77 950-956.
18. Workman A.J., Kane K.A., Rankin A.C. The contribution of ionic currents to changes in refractoriness of human atrial myocytes associated with chronic atrial fibrillation. Cardiovasc. Res. (2001) 52 226-235.
19. Nenov N.I., Crumb W.J. Jr. Pigott J.D., Harrison L.H. Jr. Clarkson C.W. Quinidine interactions with human atrial potassium channels: developmental aspects. Circ. Res. (1998) 83 1224-1231.
20. Brandt M.C., Priebe L., Bohle T., Sudkamp M., Beuckelmann D.J. The ultrarapid and the transient outward K(+) current in human atrial fibrillation. Their possible role in postoperative atrial fibrillation. J. Mol. Cell. Cardiol. (2000) 32 1885-1896.
21. Schaffer P., Pelzmann B., Bernhart E. et al. The sulphonylurea glibenclamide inhibits voltage dependent potassium currents in human atrial and ventricular myocytes. Br. J. Pharmacol. (1999) 128 1175-1180.
22. Crumb W.J. Jr. Wible B., Arnold D.J., Payne J.P., Brown A.M. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: possible mechanism for terfenadine-associated cardiotoxicity. Mol. Pharmacol. (1995) 47 181-190.
23. Crumb W.J. Jr. Rate-dependent blockade of a potassium current in human atrium by the antihistamine loratadine. Br. J. Pharmacol. (1999) 126 575-580.
24. Seki A., Hagiwara N., Kasanuki H. Effects of propafenone on K currents in human atrial myocytes. Br. J. Pharmacol. (1999) 126 1153-1162.
25. + channel current. Circ. Res. (1993) 73 210-216.
26. + current similar to Kv1.5 cloned channel currents. Circ. Res. (1993) 73 1061-1076.
27. + channel Kv1.5 by the antibiotic erythromycin.. Naunyn Schmiedebergs Arch Pharmacol. (1997) 355 743-750.
28. Courtemanche M., Ramirez R.J., Nattel S. Ionic targets for drug therapy and atrial fibrillation-induced electrical remodeling: insights from a mathematical model. Cardiovasc. Res. (1999) 42 477-489.
29. + current in rabbit and human atrial myocytes. Circ. Res. (1999) 84 551-561.
30. - current. Am. J. Physiol. (1992) 26 1967-1971.
31. Lindblad D.S., Murphey C.R., Clark J.W., Giles W.R. A model of the action potential and underlying membrane currents in a rabbit atrial cell. Am. J. Physiol. (1996) 271 1666-1696.
32. Firek L., Giles W.R. Outward currents underlying repolarization in human atrial myocytes. Cardiovasc. Res. (1995) 30 31-38.
33. Ekins S., Crumb W.J., Sarazan R.D., Wikel J.H., Wrighton S.A. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. (2002) 301 427-434.
34. Tomaselli G.F., Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc. Res. (1999) 42 270-283.
35. Lacroix D., Gluais P., Marquie C., D'Hoinne C., Adamantidis M., Bastide M. Repolarization abnormalities and their arrhythmogenic consequences in porcine tachycardia-induced cardiomyopathy. Cardiovasc. Res. (2002) 54 42-50.
36. Lu H.R, Marien R, Saels A, De Clerck F. Species plays an important role in drug-induced prolongation of action potential duration and early afterdepolarizations in isolated Purkinje fibers. J. Cardiovasc. Electrophysiol. (2001) 12 93-102.
37. Dumotier B.M., Bastide M., Adamantidis M.M. "Use-dependent" effects of cisapride on postrest action potentials in rabbit ventricular myocardium. Eur. J. Pharmacol. (2001) 422 137-148.
38. Adamantidis M.M., Dumotier B.M., Caron J.F., Bordet R. Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers. Fundam Clin Pharmacol. (1998) 12 70-76.
39. + channel protein in explanted cardiac tissue. J. Clin. Invest. (1995) 96 282-292.
40. + current human ventricular myocytes. Circ. Res. (1996) 78 689-696.